LONDON, UK (GlobalData), 12 June 2012 - The rising incidence of kidney disease due to increasing obesity, high blood pressure and diabetes is forming a gigantic market for new renal disease treatments, according to a new report by healthcare intelligence experts GlobalData.
The new report* shows no targeted therapy currently exists to slow down disease progression in patients with end-stage renal disease (ESRD), who currently rely on expensive options such as dialysis or kidney transplant. This gap in the market could therefore provide opportunities for pharmaceutical companies able to develop drugs to directly treat renal damage and slash healthcare spending.
All drug therapies available now can only provide symptomatic relief - for instance phosphate binders work to reduce dangerous serum phosphorus levels that the kidneys can no longer control themselves. However, phosphate binders Renagel (sevelamer hydrochloride), Renvela (sevelamer carbonate), Fosrenol (lanthanum carbonate) and Phoslo Gelcaps (calcium acetate) all show low patient compliance due to low efficacy and safety profiles, common side effects such as gastrointestinal intolerance, a high pill burden, and a high expense of therapy. There is therefore a distinct need for new drug treatments with improved safety and effectiveness records.
A new molecule offering disease-modifying therapy to treat the underlying causes of ESRD would reduce patient dependence on dialysis and transplantation, transforming the lives of individuals living with renal diseases. Currently, no drugs are able to restore normal kidney function, but the market eagerly waits for a revolutionary drug able to delay disease progression.
Analysis shows that the ESRD pipeline has 17 molecules in various phases of clinical development, including 13 FIC molecules, of which three are in Phase III and one is in pre-registration. MP-146 and Zerenex in Phase III and Peginesatide in the pre-registration Phase are expected to drive the market in the forecast period. Whether any of these will provide a cure and become a blockbuster drug however, remains to be seen. GlobalData estimates that the ESRD therapeutics market in the seven key markets of the US, the UK, Germany, France, Italy, Spain and Japan was worth $2.03 billion in 2011. They forecast it to grow at a Compound Annual Growth Rate (CAGR) of 0.8% to $2.16 billion by 2019.
*End Stage Renal Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2019
This report identifies the key trends shaping and driving the global ESRD market, and provides insights into the prevalent competitive landscape and the emerging players expected to significantly alter the positioning of the market leaders. Most importantly, it provides valuable insights into the pipeline products within the global ESRD therapeutics sector. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
-ABOUT GLOBALDATA-
GlobalData is a leading global business intelligence provider offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.
For more information, please contact our Press Office on +44 (0)1204 543 537 or at pr@globaldata.com
